Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruben A G van Eerden

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
International Journal of Nanomedicine|November 2, 2020
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of CancerRuben A G van Eerden, Ron H J Mathijssen, Stijn L W Koolen
Pharmaceuticals (Basel, Switzerland)|February 9, 2021
Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase InhibitorsRuben A G van Eerden, Esther Oomen-de Hoop, Aad Noordam, et al.
Cancers|June 16, 2019
Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer PatientsFemke M de Man, Ruben A G van Eerden, Esther Oomen-de Hoop, et al.
Frontiers in Genetics|July 26, 2021
<i>CYP3A4</i> Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
Clinical Pharmacokinetics|February 6, 2020
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer PatientsStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Cancers|August 7, 2021
Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634Florence Atrafi, Ruben A G van Eerden, Stijn L W Koolen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 14, 2022
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancerNiels A D Guchelaar, Ruben A G van Eerden, Stefanie L Groenland, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 18, 2024
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal originPascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, et al.
Therapeutic Drug Monitoring|October 1, 2019
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective StudyStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2020
Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid TumorsFlorence Atrafi, Ruben A G van Eerden, Marte A M van Hylckama Vlieg, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
International Journal of Nanomedicine|November 2, 2020
Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of CancerRuben A G van Eerden, Ron H J Mathijssen, Stijn L W Koolen
Pharmaceuticals (Basel, Switzerland)|February 9, 2021
Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase InhibitorsRuben A G van Eerden, Esther Oomen-de Hoop, Aad Noordam, et al.
Cancers|June 16, 2019
Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer PatientsFemke M de Man, Ruben A G van Eerden, Esther Oomen-de Hoop, et al.
Frontiers in Genetics|July 26, 2021
<i>CYP3A4</i> Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
Clinical Pharmacokinetics|February 6, 2020
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer PatientsStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Cancers|August 7, 2021
Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634Florence Atrafi, Ruben A G van Eerden, Stijn L W Koolen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 14, 2022
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancerNiels A D Guchelaar, Ruben A G van Eerden, Stefanie L Groenland, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 18, 2024
Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal originPascale C S Rietveld, Sebastiaan D T Sassen, Niels A D Guchelaar, et al.
Therapeutic Drug Monitoring|October 1, 2019
Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group-Therapeutic Drug Monitoring Protocol for a Prospective StudyStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2020
Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid TumorsFlorence Atrafi, Ruben A G van Eerden, Marte A M van Hylckama Vlieg, et al.
Pageof 2